论文部分内容阅读
目的观察尼麦角林用于老年慢性脑血管功能不全(CCVI)患者的临床治疗效果与安全性。方法 64例老年CCVI患者,采用尼麦角林施治,连续用药12周之后,评定其临床疗效,记录大脑动脉与椎动脉的收缩期血流速度(VP)、舒张末期血流速度(VE)、脉动指数(PI)数值,观察患者的不良反应。结果本组64例患者的总有效率、不良反应发生率分别为85.94%(55/64),3.13%(2/64)。治疗12周后,患者大脑动脉、椎动脉的VP、VE值与治疗前相比均显著增高(P<0.05);PI与治疗前相比明显降低(P<0.05)。结论尼麦角林可以有效缓解老年CCVI患者各项症状,改善动脉功能指标,且安全性高,有推广价值。
Objective To observe the clinical efficacy and safety of nicergoline for elderly patients with chronic cerebrovascular insufficiency (CCVI). Methods Sixty-four elderly CCVI patients were treated with nicergoline for 12 weeks. The clinical effects were evaluated. The systolic velocity (VP), end diastolic velocity (VE) Pulse index (PI) values were observed in patients with adverse reactions. Results The total effective rate and adverse reactions of 64 patients in this group were 85.94% (55/64) and 3.13% (2/64), respectively. After 12 weeks of treatment, the VP and VE of cerebral artery and vertebral artery of patients were significantly higher than those before treatment (P <0.05); PI was significantly lower than that before treatment (P <0.05). Conclusion Nicergoline can effectively relieve the symptoms of elderly patients with CCVI and improve the arterial function indexes. It is safe and has the promotion value.